Covered recipient · General Payments record
BROOKLYN BLANCHE BURAS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2025
$414.57
- Reported across 15 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $414.57 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $192.70 | 6 |
| Lilly USA, LLC | $45.58 | 2 |
| MERZ NORTH AMERICA, INC. | $42.95 | 1 |
| Galderma Laboratories, L.P. | $36.36 | 2 |
| REVANCE THERAPEUTICS, INC. | $33.16 | 1 |
| Incyte Corporation | $25.02 | 1 |
| LEO Pharma Inc. | $21.61 | 1 |
| UCB, Inc. | $17.19 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $414.57 | 15 |
Payment records · PY2025 (15)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.92 | 10/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402485 | CMS |
| ABBVIE INC. | $20.84 | 10/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402493 | CMS |
| ABBVIE INC. | $124.21 | 11/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402501 | CMS |
| ABBVIE INC. | $20.87 | 11/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402510 | CMS |
| ABBVIE INC. | $2.35 | 12/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402517 | CMS |
| ABBVIE INC. | $2.51 | 12/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1205402525 | CMS |
| Galderma Laboratories, L.P. | $13.69 | 07/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234736858 | CMS |
| Galderma Laboratories, L.P. | $22.67 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234736860 | CMS |
| Incyte Corporation | $25.02 | 11/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1225997304 | CMS |
| LEO Pharma Inc. | $21.61 | 09/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1252051978 | CMS |
| Lilly USA, LLC | $24.56 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186994330 | CMS |
| Lilly USA, LLC | $21.02 | 10/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186961582 | CMS |
| MERZ NORTH AMERICA, INC. | $42.95 | 10/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1236977699 | CMS |
| REVANCE THERAPEUTICS, INC. | $33.16 | 08/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251179601 | CMS |
| UCB, Inc. | $17.19 | 12/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224455398 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.